Friday, April 11, 2014

Piramal Healthcare’s 11% Vodafone Stake – Definitely worth it!

A little over 2 years ago I had written an article talking about Piramal's acquisition of an 11% stake in Vodafone India titled "Piramal Healthcare’s 11% Vodafone Stake – Is it worth it?". With the final conclusion of the sale of Vodafone, we can definitely say "Definitely Worth It".

But what does this mean to the stock price of Piramal? It has already risen 5% for two consecutive days since the announcement. So is the valuation just about right? Or is there an more room for growth? These are the questions a wannabe investor of Piramal must be asking himself.

In my opinion, Piramal is again at the same stage it was 2 years back. They have made a capital gain of around 2000 crores after tax on the transaction and further bolstered their coffers. They are again poised in investing these funds in their existing business or a new venture and get a decent ROE. All that we can know probably during their next analyst presentation/call.

But the Book Value of the company keeps increasing. The market cap is still INR 10,000 crore whereas their Vodafone investment itself was worth INR 8900 crore. Hence in my opinion, this still remains a BUY!

Thursday, June 21, 2012

Piramal Healthcare acquisition of Decision Resources Group - An attempt to value DRG


With Piramal Healthcare stock slowly and steadily marching northwards (Disclaimer: It has been my favorite stock for almost a year, so this post may be a little biased ) following a slew of acquisitions (and a Rs17.5 dividend per share coming up), I once again pause to take a look at the latest acquisition – Decision Resources Group for a sum of approximately $635 million. All the reasons given in their investor presentation indicate the attractiveness of holding this company in the portfolio. But again the question arises (as earlier with Vodafone India’s stake), have they paid an appropriate value for this? So, I make an attempt to value DRG, but the same being a privately held company a lot of assumptions need to be made.

Wednesday, June 20, 2012

Analysis of Navin Flourine International Ltd


A company giving Rs66.5 per share dividend in form of (final + special) dividend always attracts attention. Since its announcement it has risen from 330 to 430 and post ex-date, it now trades at 305. Its P/E multiple shows 1.xx and it reported a fantastic result as follows:

Navin Fluorine International Limited, a part of reputed industrial house of Arvind Mafatlal Group, today reported a consolidated net profit of Rs. 217.58 crore for the year ended March 31, 2012 as against Rs. 71.34 crore in corresponding period of last fiscal year, registering an increase of 205 %.
Net Revenue for the year stood at Rs. 7.24bn, registering a growth of 68.23 % as compared to Rs. 4.30bn posted the last fiscal year. Earnings per share (EPS) increased by 214 % to Rs. 222.91 as compared to Rs. 70.81  of the last fiscal year.
(source: http://www.indiainfoline.com/Markets/News/Navin-Fluorine-FY12-net-profit-jumps-68-percent/5407635849)

The big question coming to my mind is: “Why then is this stock not catching the imagination of the prudent investors?” The answer becomes apparent on looking at its annual report.

Sunday, February 5, 2012

Piramal Healthcare’s 11% Vodafone Stake – Is it worth it?


Piramal Healthcare on Friday added 5.5% stake to Vodafone India to take its total shareholding in the telecom major to 11%. Now, Piramal’s total investment in Vodafone i.e. telecom business stands at Rs5870 crore. Considering this to be almost equivalent to a third of the sale proceeds to Abbot, I wanted to estimate how much is Vodafone actually worth (Neglecting the effect Supreme court ruling cancelling 2G licenses issued in 2008 could have on its value). 

Data used for the relative valuation is taken from Vodafone Plc’s half yearly numbers, wherein Sales and EBITDA of India operations was given. As for comparison, MarketCapitalization/Sales and EV/EBITDA are considered. The comparable companies which have been taken for this are Airtel, Idea, RComm and Tata Teleservices (TTML). The values for the multiples as on 25th Jan 2012 were:


EV/EBITDA
Mkt Cap/Sales
Airtel
11.13
3.57
Idea
10.79
1.45
Rcomm
31.54
1.67
Tata Tele
6.78
1.44
Average
9.57*
2.03

Wednesday, February 1, 2012

Mahindra Satyam Ltd Results – What to expect tomorrow?


Satyam came out with their Q3 results after the end of trading today. The salient points in their result are:
  1. Consolidated Revenue up 34% YoY and 9% QoQ at Rs1718 Crore
  2. Consolidated PAT stood at Rs 308 Crore, a rise of 29% QoQ and 424% YoY
A major point to be noted is that the pre-tax “Other Income” surged by 56.4% to Rs 151.3 crore. The EBITDA stood at increased by a relatively modest 15.1%. The EPS for Q3 was reported at Rs 2.62. The nine month EPS stood at Rs 6.56. In absence of Q4 guidance, for a back-of-the-envelope calculation, if we annualise this EPS, we get an EPS of Rs 8.75. But on the other hand, if a performance equivalent to this quarter were to come (flat QoQ growth), then the EPS for the year ending March 2012 would stand at Rs 9.18. 

Now, the IT industry average P/E multiple is around 20, while at the present annualised P/E multiple, Satyam trades at 8.7. Considering the P/E multiple based upon the H1 EPS which stood at 2.52 (Annualised value of Rs 5.04), the stock was trading at a multiple of 15. With the better results for the company in the last quarter (EPS for Q3 was greater than that of H1 combined) the stock would be trading at a far lower multiple of 9 if it does not grow tomorrow.

Hence, I would buy Satyam and set a target of Rs 100-110 (When a current P/E multiple of 12-13 would be achieved).

Friday, January 13, 2012

Infosys Q3 FY12 Results – Is the 8.4% fall justified?

Consolidated results for the quarter ended December 31, 2011 were reported by Infosys today. The highlights of the same are:

1) Revenues were Rs 9,298 crore for the quarter ended December 31, 2011; QoQ growth was 14.8%; YoY growth was 30.8%
2) Net profit after tax was Rs 2,372 crore for the quarter ended December 31, 2011; QoQ growth was 24.4%; YoY growth was 33.3%
3) Earnings per share (EPS) was Rs 41.51 for the quarter ended December 31, 2011; QoQ growth was 24.4%; YoY growth was 33.3%

The results beat most of the market expectation. But the flat earnings projection (QoQ) for the last quarter of the year owing to volatile economic environment especially in the Euro zone dampened the mood and the stock of the company fell 8.4% by the end of the trading session. Now the question is: Is this fall justified?
Let us take a look at the Q4 guidance given by Infosys:
1)     Revenues are expected to be in the range of Rs 9,391 crore and Rs 9,412 crore
2)     Earnings per share (EPS) is expected to be Rs 42.12

Although this is almost flat QoQ, but if we consider the YoY implications of this guidance, revenues are expected to grow by 29.5% to 29.8% and EPS by 32.4%. This is a rather impressive YoY growth which was last seen during FY2008-09 for Infosys. For the past two years, the EPS growth was rather sluggish as compared to this. But is this stock fall owing to a drastic reduction in value of the company?

Thursday, August 4, 2011

Analysis of Piramal Healthcare Ltd

Piramal Healthcare, in their Analyst presentation came out with their future strategy of utilizing their cash. As mentioned in my earlier post, they are sitting on almost Rs 10,000 crore cash/cash equivalent. With the sale of the Domestic Formulations business, there was some anxiety as to which business would Mr Piramal decide to invest the money in.

The major focus of the investments lies in four areas as follows:

1) Pharma Solutions
Investment: Rs 2,700 Crore
Current Sales: Rs 1020 Crore
Sales Target: Rs 5,000 Crore by 2016 (CAGR of 37%)

They aim to be among the top-3 contract manufacturing organizations globally.

Thursday, July 28, 2011

Analysis of L&T Finance IPO

L&T Finance has generated quite a bit of hype for its IPO. Due to lack of time, I have not been able to make a better study of the same and hence valuation. Hence, I will restrict myself to a relative valuation this time around.

For this purpose, I shall use the companies that they have mentioned in the RHP. The various figures for them is mentioned below.


EPS
Price (as on 27/07/11)
P/E
RONW
Book Value(BV) Per Share
P/BV
Shriram Trans. Fin.
53.92
665.90
12.35
24.87%
216.37
3.08
M&M Financial Serv.
50.92
689.95
13.55
19.36%
244.70
2.82
IDFC
8.77
133.70
15.25
11.39%
76.97
1.74
Rural Elect. Co
26.18
213.60
8.16
20.15%
129.90
1.64
PFC
23.06
192.50
8.35
17.37%
132.79
1.45
Sundaram Finance
70.01
570.05
8.14
21.53%
325.22
1.75
L&T Finance
2.87
59
20.56
13.58%
20.4
2.89

Wednesday, July 27, 2011

Analysis of Great Offshore Ltd Results


I was pleasantly surprised when Great Offshore came out with the results today stating their net profit was up from Rs 26.73 Cr to Rs 54.90 Cr, a whopping 105% growth Y-o-Y. Amidst the relatively poor showing by the industry in the recent past, this seemed a silver lining. But on closer inspection, these clouds of delight evaporated.

Their income from operations was down from Rs 235.9 Cr to Rs 218.59 Cr. But the contributor to their bottom line was not their operations, but profit from sales of vessels, which amounted to Rs 47.85 Cr before tax. Now if we remove this figure from the PBT, the amount goes down from Rs 92.9 Cr to Rs 45.05 Cr. And this is excluding the taxes. If we consider 40% corporate tax (the amount by which they deducted their tax), the PAT comes down to Rs 27.03 Cr.

Thus, the actual growth of the company was by a marginal 1.12%. Considering this, their EPS for Q1 was 7.26. The stock of the company was down by 1.05% at 211.85, trading at a current PE multiple of 7.29, which considering the lack of significant operational growth can be justified.

For the moment, I would rather stay away from this stock.

Tuesday, July 26, 2011

Analysis of Opto Circuits India Ltd Results


Opto Circuits India Ltd is a medical equipment manufacturer with presence in India and Abroad. The Q1 results for the same were exceedingly good. On a Y-o-Y standalone basis, net profit increased marginally from Rs 56.95 Cr to Rs 57.13 Cr. But the more attractive figures come from the consolidated results. The net profit has increased from Rs 83.09 Cr to Rs 116.38 Cr (Y-o-Y). This has led to an EPS increase from Rs 4.46 to Rs 6.24.

Opto Circuits India Ltd, in itself has not grown much and is itself purely in healthcare segment. But the subsidiaries are more attractive with interests in IT as well. The most important information out of the results is the exceedingly good performance by the subsidiaries. The profit from the subsidiaries has increased from Rs 26.14 Cr to Rs 59.25 Cr, indicating a whopping growth of 126%. The International Health care business has reported a significant gain in revenues by almost 51%. 

The most significant concern for the company could be exchange rate risk, as the majority of the sales as well as the profits come from the international business. Profits from domestic segment as well as the margins here are very small.

The current EPS (I assume it to be 4 times latest EPS) is 24.96. This means that the stock is currently trading at a PE multiple of around 11, which is very low as compared to the industry (20.8). Moreover, for such a growth rate that they are experiencing, Opto Circuits may be considered a value buy.

I will post a better analysis as soon as I get their annual report for FY2010-11 and have a look at their balance sheet.

Friday, July 22, 2011

Analysis of Biocon Ltd Results

When I first saw the FY11 Q1 results of Biocon, I was really disappointed. But on taking a closer look, there were some positives as well. Although the standalone net profit was down from Rs 72.3 crores to Rs 60.4 crores, their consolidated net profit from continuing operations (their subsidiary had sold its subsidiary) was marginally up by 7% from Rs 65.22 crore to Rs 70.05 crore. These figures indicate two important things:

1)    The domestic profitability has taken a hit
2)    The subsidiaries, many of whom are foreign, have turned profitable

Tuesday, July 19, 2011

Analysis of Piramal Healthcare Ltd

When I decided to value Piramal Healthcare (PHL), a question came to my mind: "How do you value a company that is sitting on a cash pile of Rs 596 per share, when it is trading at Rs 403 per share?"

With such a strong cash position and the current EPS (of the business remaining after the Abbott sale) being 39.2 (4xEPS of Q4), the current P/E ratio of the company is 10.3. Such a P/E ratio for a company, with a proven track record is significantly lower than its peers (with equivalent track record). Such a low P/E multiple indicates that the 'market' does not expect the company to grow significantly in the future, which is unlikely considering their management track record.

Tuesday, July 5, 2011

Valuation of Biocon Ltd

Valuation of a company is not a straightforward task. There is no particular formula that will give a fixed value for the share of the company. I have tried using DCF (Discounted Cash Flow) method for valuing Biocon Ltd.

In the process of arriving at a particular value, several assumptions are required to be taken. I have tried to keep those assumptions as conservative as possible. The assumption for the same are as follows:

1) CAGR of Sales for the next 5 yrs: 25% (The past 5 yr average for Biocon is 28%, with growth touching 40% in the yr before last)

2) Target Operating Profit Margin of 20% (Past 5 yr avg for Biocon is over 25%. Most of the global players have the same closer to 30%)

3) Sales to capital ratio: 1.16 (Past 5 yr average for Biocon)

4) As the debt ratio of Biocon is very low (less than 0.1), for simplicity, I have taken the cost of capital as the cost of equity, which I obtained using the CAPM model.

5) The terminal value of the return on capital is assumed to be 15.5%. This is much lower than current ROIC of Biocon which is 22%

6) I have considered tax rate as 34% [as Biocon is a domestic company. This rate is supposed to further go down after implementation of the Direct Tax Code]

Considering the above mentioned assumptions, the final value I obtained for Biocon Share was Rs 435. The valuation depends a lot on the assumptions, but I believe the assumption that I have considered for the valuation of Biocon are conservative.

Excel sheet containing the calculation:  Biocon Valuation

If you have any comments, please shoot :)

Sunday, July 3, 2011

Analysis of Compact Disc India Ltd

The uncertainty in the delisting of Compact Disc Ensues. Last month, HSBC Bank, bankers to the firm brought a stay order to the proposed voluntary delisting. This may mean several things, the first of which comes to my mind (i am speculating here) is the fact that the bankers may have lost faith in ability of the company to pay back and they feel that the money is being unnecessarily used to buy-back shares instead of doing something productive.

It is always tough for a company, if their banker, a reputed name in the industry shows such signs. This may hinder further raising of finances for the company. On a long run this may harm the growth of the company.

Moreover the resignation of key personnel from the board sends the wrong message. As mentioned in my previous post, the target of 60 (based upon the past 26 week avg) had been passed. Now if the delisting does not come about, any appreciation of price may not come up.

Despite of the good figures in the book of the company i shall recommend not to go in for the shares of the company.

Sunday, January 30, 2011

News on Compact Disc India Ltd

Delisting
Compact Disc India Ltd has informed BSE that the Board of Directors of the Company at its meeting held on January 28, 2011, inter alia, approved and adopted the following:

1. Board has approved the delisting of its equity from the Stock Exchanges where the securities of the company are listed. The Board convened an Extraordinary General Meeting on March 22, 2011 for approval from the esteemed shareholders. The reason for delisting shall be specified in the EGM notice.

I would like to remind the readers that for delisting, the company has to give a buy-back offer to the public as an exit opportunity as per a SEBI regulation.  CDI has sufficient Reserves to accomplish this successfully. The minimum floor price of the offer is the 26-week average of the stock price, which in this case is around Rs58-59.

Friday, January 21, 2011

News on Compact Disc India Ltd

Board Meeting on Jan 28, 2011 | 20/01/11 18:02

Compact Disc India Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on January 28, 2011, inter alia, to consider the following matters:

1. To consider and approve unaudited financial results of the Company for the quarter ended December 31, 2010.

2. To consider and approve the delisting of the securities of the Company from Bombay Stock Exchange and other stock exchanges where the securities of the company are listed.

3. To consider and convene the Extra Ordinary General Meeting of the members of the Company.
-----------------------------------------------------------------------------------------------------

My Analysis:
If the "Delisting of the shares is approved by the board on 28th, as per SEBI rules, they will have to give a Buy Back offer as an Exit opportunity for the shareholders.

The price of the buy back offer is decided by the book building process, where the floor price is the past 26 week average. Now, for Compact Discs India Ltd, the 26 week average is around Rs 60. So hold on to shares till they reach 60.

Happy Investing!!

Friday, January 14, 2011

News on Lupin Ltd

Lupin receives FDA Approval for Nabumetone tablets  | 14/01/11
[Source: www.bseindia.com ]

Lupin Limited announced today that its U.S subsidiary, Lupin Pharmaceuticals, Inc. (LPI) has been granted final approval for its Nabumetone tablets, 500 mg and 750 mg strengths from the U.S. Food and Drug Administration.

Lupin’s Nabumetone is the AB-rated generic equivalent of GlaxoSmithKline’s RELAFEN tablets indicated for acute and chronic treatment of the signs and sympto of osteoarthritis and rheumatoid arthritis.  Annual sales for the Nabumetone market in the US was $66.8 mn for the twelve months ended September 2010, based on I Health sales data.

Wednesday, January 12, 2011

November 2010 IIP Figures

The Ministry Of Statistics and Program Implementation has released the IIP estimates for November 2010. The Press Note is as follows:
------------------
The Quick Estimates of Index of Industrial Production (IIP) with base 1993-94 for the month of November 2010 have been released by the Central Statistics Office of the Ministry of Statistics and Programme Implementation. The General Index stands at 317.9, which is 2.7% higher as compared to the level in the month of November 2009. The cumulative growth for the period April- November, 2010-11 stands at 9.5% over the corresponding period of the previous year.

The Indices of Industrial Production for the Mining, Manufacturing and Electricity sectors for the month of November 2010 stand at 205.8, 343.9, and 230.5 respectively, with the corresponding growth rates of 6.0%, 2.3% and 4.6% as compared to November 2009. The cumulative growth during April-November, 2010-11 over the corresponding period of 2009-10 in these three sectors have been 8.0%, 10.0% and 4.5% respectively, which moved the overall growth in the General Index to 9.5%.
 
In terms of industries, nine (9) out of the seventeen (17) industry groups (as per 2-digit NIC-1987) have shown positive growth during the month of November 2010 as compared to the corresponding month of the previous year. 

The industry group ‘Transport Equipment and Parts’ have shown the highest growth of 15.6%, followed by 12.6% in ‘Leather and Leather & Fur Products’ and 9.6% in ‘Other Manufacturing Industries’. 

On the other hand, the industry group ‘Wood and Wood Products; Furniture and Fixtures’ have shown a negative growth of 27.4% followed by 17.5% in ‘Jute and other vegetable fiber Textiles (except cotton)’.
 
 As per Use-based classification, the Sectoral growth rates in November 2010 over November 2009 are 4.5% in Basic goods, 12.6% in Capital goods and 2.4% in Intermediate goods. The Consumer durables and Consumer non-durables have recorded growth of 4.3% and (-) 6.0% respectively, with the overall growth in Consumer goods being (-) 3.1%.

5. During the current month, low growth has been observed in Intermediate goods and Consumer non-durable goods. Important items registering highly negative growth include ‘Spun pipes’ [(-) 38.2%], ‘Railway/concrete sleeper’ [(-) 34.9%] and ‘Particle board’ [(-) 29.6%] in case of Intermediate goods and
‘Rice bran oil’ [(-) 57.9%] and ‘Hair oil/ayurvedic hair oil’ [(-) 42.5%] in case of Consumer non-durable goods. Moreover ‘Agricultural implements’ [(-) 55.6%] and ‘Industrial machinery’ [(-) 46.7%] of Capital goods are also showing highly negative growth.

------------------




Friday, January 7, 2011

News on Lanco Infratech Ltd

Lanco Infratech's successful Bid | 30/12/10

Lanco Infratech Ltd has informed BSE that:
"Lanco Infratech Limited (LITL), has emerged as successful Bidder for 2 Laning with paved shoulders of Aligarh to Kanpur Section of NH-91 from KM 140.000 to KM 418.162 in the State of Uttar Pradesh on Design, Build, Finance, Operate and Transfer (DBFOT) on Toll Basis of National Highways Authority of India (NHAI).

The Scope of Work involves 2 Laning with paved shoulders of existing road, repair, widening and reconstruction of 3 major & 29 minor bridges, construction of 5 new Rail-over-Bridges, 4 toll plazas and other wayside amenities.

The Project involves an investment of around Rs. 1,000 Crores. The Grant from NHAI would be Rs. 287.91 Crores. The concession period for the Project is 12 Years including a Construction Period of 18 Months. The concessionaire will have the right to collect toll over the entire concession period starting from the Commercial Operations Date of the Project."

News on Lupin Ltd

Lupin signs strategic agreement with FARMANGUINHOS, Brazil | 05/01/11
[Source: www.bseindia.com ]

Lupin Ltd announced that it has entered into an agreement with Farmanguinhos, Brazil's largest PSU in health care for the supply of its 4 in 1 combination drug of Rifampicin, Isoniazide, Ethambutol and Pyrazinamide for tuberculosis. Lupin will supply the product for the next five years and also provide Farmanguinhos with the desired support for the set up of its local manufacturing in future.

With this agreement between Lupin and Farmanguinhos in place, Farmanguinhos has entered into a commitment to produce and supply the 4 in 1 combination drug to the Department of Health (Brazil), which will result in substantial savings for the government.

The 4 in 1 combination reduces the pill burden on the patient drastically, particularly as the treatment lasts for at least six months. As per WHO, the treatment abandonment rate has fallen from 8 per cent to only 5 per cent due to this reduced pill burden provided by the combination drug. WHO estimates indicate that globally there are 9.2 million new cases each year resulting in 1.7 million deaths.